摘要
目的探讨阿法替尼联合培美曲塞+卡铂(AC)化疗方案治疗晚期敏感性表皮生长因子受体(EGFR)突变肺腺癌的临床效果。方法本研究为前瞻性随机对照研究。纳入2020年1月至2022年10月收治的52例晚期敏感性EGFR突变肺腺癌患者,以随机数字表法分为对照组(26例,AC化疗方案治疗)和观察组(26例,AC化疗方案+阿法替尼治疗),均持续治疗6个疗程。比较2组疗效、肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)]水平、EGFR水平,对比2组治疗期间副作用发生情况,并统计随访12个月患者生存情况。结果治疗6个疗程时,对照组缓解率低于观察组(P<0.05);对照组CEA、CYFRA21-1水平高于观察组(P<0.05);对照组EGFR水平高于观察组(P<0.05)。随访12个月内,对照组无进展生存时间短于观察组(P<0.05);经Log Rank检验,2组总生存时间比较,P<0.05。结论晚期敏感性EGFR突变肺腺癌患者采用AC化疗方案联合阿法替尼治疗的效果显著,可降低EGFR水平和肿瘤标志物水平,延长生存时间。
Objective To explore the clinical efficacy of the combination of afatinib,pemetrexed,and carboplatin(AC)chemotherapy regimen in the treatment of advanced sensitive epidermal growth factor receptor(EGFR)mutated lung adenocarcinoma.Methods This study was a prospective randomized controlled study,52 patients with advanced sensitive EGFR mutation lung adenocarcinoma were selected and randomly divided into the control group(26 cases,AC chemotherapy regimen treatment)and the observation group(26 cases,treated with AC chemotherapy regimen and afatinib)using a random number table method,all groups were treated continuously for 6 courses.The efficacy,levels of tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],and EGFR levels were compared between the 2 groups.The incidence of side effects during treatment were compared between the 2 groups,and the survival of patients followed up for 12 months were statistically analyzed.Results After 6 courses of treatment,the remission rate in the control group was lower than that in the observation group(P<0.05).The levels of CEA and CYFRA21-1 in the control group were higher than those in the observation group(P<0.05).The EGFR level in the control group was higher than that in the observation group(P<0.05).Within 12 months of follow-up,the control group had a shorter progression free survival time than the observation group(P<0.05).Comparison of total survival time between the 2 groups based on Log Rank test(P<0.05).Conclusion The combination of AC chemotherapy and afatinib has a significant effect on advanced sensitive EGFR mutated lung adenocarcinoma patients,which can reduce EGFR levels and tumor marker levels,and prolong survival time.
作者
谢灵灵
王永豪
左一凡
XIE Lingling;WANG Yonghao;ZUO Yifan(General Hospital of Pingmei Shenma Group,Pingdingshan,467000)
出处
《实用癌症杂志》
2024年第9期1502-1505,共4页
The Practical Journal of Cancer
关键词
阿法替尼
培美曲塞
卡铂
表皮生长因子受体
肺腺癌
Afatinib
Pemetrexed
Carboplatin
Epidermal growth factor receptor
Lung adenocarcinoma
